Harbour BioMed Partners with Lannacheng for Next-Gen Radionuclide Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2025
0mins
Source: PRnewswire
- Strategic Collaboration: Harbour BioMed has entered a long-term strategic partnership with Lannacheng to jointly advance the development of next-generation radionuclide drug conjugates (RDCs), leveraging their respective resources and strengths to enhance the efficiency of tumor-targeted therapies.
- Technological Advantage: RDCs utilize tumor antigen-specific ligands to deliver radionuclides directly to tumor lesions, significantly reducing damage to surrounding healthy tissues and providing a more targeted treatment option compared to conventional radiotherapy.
- R&D Integration: The collaboration combines Harbour BioMed's Harbour Mice® platform with Lannacheng's radiopharmaceutical R&D capabilities, aiming to accelerate the development of more precise and safe cancer therapies, thereby improving patient outcomes.
- Market Potential: This partnership not only aims to drive new drug development but also brings new hope to cancer patients worldwide, highlighting both companies' innovative potential and competitive strength in the biopharmaceutical sector.
Analyst Views on 02142
Wall Street analysts forecast 02142 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02142 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 14.380
Low
Averages
High
Current: 14.380
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
